Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Inclusion Criteria: * Age \>= 18 years * Histologically proven of relapsed or refractory * Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) nodal or extranodal mass OR * Cutaneous T-cell lymphoma (CTCL) including mycosis fungoides (MF), as well as transformed MF OR * Breast adenocarcinoma with nodal or cutaneous metastases (stage 4) * NOTE: Patients must be refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for their condition * NOTE: The patient must not be a candidate for any curative therapy or any known life-prolonging therapy * Cohort I: For nodal/extranodal mass, presence of lesions that are amenable for injections as determined by interventional radiology * NOTE: Nodal or extranodal mass must be palpable and easily accessible; masses such as mediastinum, retroperitoneum, within solid organs, spinal sites, central nervous system (CNS) sites, etc., are NOT allowed * Measurable disease: * For nodal or extranodal disease (lymphoma or breast): must have at least 2 lesions that are \>= 20 mm (2.0 cm) in the longest diameter by physical exam and/or on cross-sectional imaging and measurable in two perpendicular dimensions per computed tomography PET-computed tomography (CT); For Cohort I, the lesions must be amenable to intralesional injections as determined by interventional radiology (including tumors that can be safely accessed using imaging guidance and treated with minimal risk to adjacent structures) * For c…